Displaying all 5 publications

Abstract:
Sort:
  1. Lee SC, Tang IP, Singh A, Kumar SS, Singh S
    Auris Nasus Larynx, 2009 Dec;36(6):709-11.
    PMID: 19304419 DOI: 10.1016/j.anl.2009.02.002
    Choanal stenosis has recently been recognized as a late complication of radiation therapy for nasopharyngeal carcinoma. The management of velopharyngeal stenosis is challenging with high risk of restenosis. We report a case of velopharyngeal stenosis post-radiotherapy and illustrated the use of mitomycin-C to prevent restenosis. Mitomycin-C application has being shown useful adjunct to surgical technique in managing nasopharyngeal stenosis for surgeons.
    Matched MeSH terms: Mitomycin/administration & dosage
  2. Wan Norliza WM, Raihan IS, Azwa JA, Ibrahim M
    Cont Lens Anterior Eye, 2006 Sep;29(4):165-7.
    PMID: 16938484
    To report a case of scleral melting noted 16 years after pterygium excision with postoperative adjuvant topical Mitomycin C (MMC).
    Matched MeSH terms: Mitomycin/administration & dosage*
  3. Narasimha K
    Gan To Kagaku Ryoho, 1992 Jul;19(8 Suppl):1220-3.
    PMID: 1514835
    Matched MeSH terms: Mitomycin/administration & dosage
  4. Hooi ST, Hooi SH
    Med J Malaysia, 2003 Oct;58(4):565-78.
    PMID: 15190633
    A retrospective study was conducted at the Hospital Sultanah Aminah Johor Bahru to determine the outcome of trabeculectomy surgeries over a period of 4 years. One hundred and two eyes were followed up to a maximum of 63 months (mean 34.2 months). The 2-year survival rates for plain trabeculectomies, 5-Fluorouracil augmented trabeculectomies and Mitomycin-C augmented trabeculectomies were 52.9%, 27.3% and 60.5% respectively. The commonest complications noted were cataract formation (25%) and hyphaema (11%). Mitomycin-C induced complications were rarely seen. At last follow-up, 54% of eyes had intraocular pressures below 21 mmHg without medication, while 34% of eyes had intraocular pressures below 21 mmHg with medication. Vitreous at the trabeculectomy site was a statistically significant predictor of operative failure.
    Matched MeSH terms: Mitomycin/administration & dosage
  5. Baratti D, Kusamura S, Azmi N, Guaglio M, Montenovo M, Deraco M
    Ann Surg Oncol, 2020 Jan;27(1):98-106.
    PMID: 31691116 DOI: 10.1245/s10434-019-07935-2
    BACKGROUND: The Prodige-7 trial has questioned the role of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal metastases from colorectal cancer (CRC-PM).

    PATIENTS AND METHODS: We compared a prospectively collected group of 48 patients undergoing oxaliplatin/irinotecan-based perioperative systemic chemotherapy (s-CT) with targeted agents, and cytoreductive surgery (CRS) (no-HIPEC group) with 48 controls undergoing the same perioperative s-CT and CRS/HIPEC (HIPEC group). Patients were matched (1:1) according to the Peritoneal Surface Disease Severity Score, completeness of cytoreduction, history of extraperitoneal disease (EPD), and Peritoneal Cancer Index.

    RESULTS: The groups were comparable, except for a higher number of patients in the HIPEC group with World Health Organization performance status 0, pN2 stage primary tumor, and treated with preoperative s-CT. Forty-one patients in the no-HIPEC group and 43 patients in the HIPEC group had optimal comprehensive treatment (P = 0.759), defined as complete cytoreduction of PM and margin-negative EPD resection. Median follow-up was 31.6 months in the no-HIPEC group and 39.9 months in the HIPEC group. Median overall survival was 39.3 months in the no-HIPEC group and 34.8 months in the HIPEC group (P = 0.702). In the two groups, severe morbidity occurred in 14 (29.2%) and 13 (27.1%) patients, respectively (P = 1.000), with no operative deaths. On multivariate analysis, left-sided primary and curative treatment independently correlated with better survival while HIPEC did not (hazard ratio 0.73; 95% confidence interval 0.47-1.15; P = 0.178).

    CONCLUSIONS: Our results confirmed that, in selected patients, perioperative s-CT and surgical treatment of CRC-PM resulted in unexpectedly high survival rates. Mitomycin C-based HIPEC did not increase morbidity but did not impact prognosis.

    Matched MeSH terms: Mitomycin/administration & dosage
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links